ABSTRACT
INTRODUCTION
Congestive heart failure is an important cause of morbidity and mortality. In patients with heart failure, excess free-radical generation may arise from many sources [1] .
Markers of oxidative stress such as thiobarbituric acid reactive substances and 8-isoprostaglandin F2-α are elevated in the blood and pericardial fluid, and levels of these markers correlate with the functional severity of heart failure [2, 3] . Advanced glycation end products (AGE) are generated nonenzymatically by glycation and oxidation of proteins [4] .
METHODS

Study subjects
We measured serum concentration of soluble RAGE in 160 patients (95 male and 65 female, mean age 69 ± 12 years) admitted to the Yamagata University Hospital for the treatment of worsening heart failure or for diagnosis and pathophysiological investigations of heart failure or for therapeutic evaluation of heart failure. Some of the patients were overlapped with a previous study from our institution [9] . The diagnosis of heart failure was based on a history of dyspnea and symptomatic exercise intolerance with signs of pulmonary congestion or peripheral edema or documentation of left ventricular enlargement or dysfunction by chest X-ray, echocardiography or left ventriculography [16] . We excluded patients with acute coronary syndrome occurring within the 3 months preceding admission, inflammatory disease, autoimmune disease, malignant disease and renal dysfunction (creatinine > 2 mg/dl). Written informed consent was obtained from all patients, and the study protocol was approved by Institutional Review Board on human research.
The etiologies of heart failure were identified as dilated cardiomyopathy in 47 patients (29%), ischemic heart failure in 42 patients (26%), valvular heart disease in 35 patients (22%), tachycardia-induced heart failure in 17 patients (11%), hypertensive heart 6 disease in 16 patients (10%) and hypertrophic cardiomyopathy in 3 patients (2%). Severity of New York Heart Association (NYHA) class was assessed by independent proficient cardiologists at initial inclusion in the study. There were 33 (21%), 63 (39%), 51 (32%) and 13 patients (8%) with NYHA class I, II, III and IV, respectively. Hypertension, diabetes mellitus, hyperlipidemia and current smoking were identified in 87 (54%), 39 (24%), 32 (20%) and 36 (23%) patients, respectively. Hypertension was defined as elevated systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or when patients had taken antihypertensive drugs. Diabetes mellitus was defined as an increased fasting plasma glucose concentration of >126 mg/dL, glycosylated hemoglobin of >6.5%, or when patients undergo treatment with insulin or hypoglycemic agents.
Hyperlipidemia was defined by total cholesterol ≥ 220 mg/dl, triglyceride ≥ 150 mg/dl, high density lipoprotein < 40 mg/dl, or current use of antihyperlipidemia drugs. Current smoking was defined by self-report.
Echocardiographic studies
We performed conventional two-dimensional echocardiographic studies using standard techniques. Left ventricular end-diastolic volume (LVEDV) and left ventricular ejection fraction (EF) was calculated based on Simpson's rule.
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Measurements of soluble RAGE and pentosidine
The serum soluble RAGE concentration in patients with heart failure were measured using a commercially available enzyme-linked immunosorbent assay kit (Quantikine, R&D systems, Minneapolis, MN, USA) in duplicate according to the manufacturer's protocol.
Serum pentosidine level was measured as reported previously [9] .
End-points and follow-up
Median follow-up period was 872 days (range 17 to 1095 days). Events were centrally adjudicated using medical records, autopsy reports, death certificates, and witness statements. The endpoints, which were judged independently by researchers, were (1) cardiac death, defined as death from worsening heart failure or sudden cardiac death, and (2) re-hospitalization with worsening heart failure [16, 17] . Sudden cardiac death was defined as death without definite premonitory symptoms or signs and was established by the attending physician. Patients were contacted after the initial presentation by telephone interview performed by trained researchers.
Statistical analysis
Soluble RAGE, pentosidine and BNP are reported as median and interquartile 8 range. Other values are expressed as mean ± SD. A P value less than 0.05 was considered statistically significant. Significance between two groups was determined by Mann-Whitney test for continuous variables and chi-square test for discrete variables. The
Cox proportional hazard regression model was used to determine which variables were associated with cardiac events. The variables with P values less than 0.05 in the univariate Cox regression analysis were entered into the multivariate Cox regression analysis.
Kaplan-Meier survival analysis was used to compare cardiac event free rates among two groups stratified by levels of serum soluble RAGE concentration and analyzed by a log-rank test. All analyses were performed using a Stat View statistical software package (version 5.0, SAS Institute Inc.).
RESULTS
In baseline clinical characteristics of study subjects, serum creatine was 0.88±0.28 mg/dl, serum pentosidine was 32.0 (22.8-44.8) ng/ml, and plasma BNP was 305 (68-741) pg/ml. LVEDV was 149±57 ml, and EF was 48±19%. Median serum soluble RAGE level was 1066 pg/ml and interquartile range was 669-1733 pg/ml. As shown in Figure 1 During follow-up periods (median 872 days, range 17 -1095 days), there were 48 cardiac events including 11 cardiac deaths and 37 re-hospitalizations due to worsening of heart failure. Table 1 shows comparisons of clinical characteristics between patients with cardiac events and event free patients. Patients with cardiac events were older (P = 0.044) and had more severe NYHA functional class (P < 0.0001) than event free patients. Serum 10 soluble RAGE level, plasma BNP level, serum pentosidine level and LVEDV were significantly higher in patients with cardiac events than event free patients.
We examined receiver operating characteristic (ROC) curve analysis and determined the cut-off value of serum soluble RAGE levels to predict cardiac events. As shown in Figure 2 , the cut-off value of serum soluble RAGE was 1220 pg/ml (sensitivity 0.60 and specificity 0.69). Next, patients with heart failure were divided into two groups based on the cut off value of serum soluble RAGE level (1220 pg/ml). High and low soluble RAGE level groups included 64 and 96 patients, respectively. Comparisons of clinical characteristics between two groups are shown in Table 2 . In high soluble RAGE level group, NYHA functional class was more severe (P = 0.0006). In high soluble RAGE group, BNP was higher and EF was lower than in low soluble RAGE group. Age, gender, etiology of heart failure, prevalence of hypertension, diabetes mellitus and hyperlipidemia were not different between two groups. Use of β-blockers and loop diuretics was significantly higher in high soluble RAGE group than in low soluble RAGE group. During follow-up periods, cardiac events were more frequently occurred in high soluble RAGE group than in low soluble RAGE group (45% vs. 20%, P = 0.0006). Positive and negative predictive values of our determined cut-off value were 0.45 and 0.80, respectively. As shown in Figure 3 , Kaplan-Meier analysis clearly demonstrated that the high soluble RAGE group had a significantly higher 11 incidence of cardiac events than occurred in the low serum soluble RAGE group (P = 0.0004 by a log-rank test).
We evaluated correlation between soluble RAGE level and BNP, EF and pentosidine by linear regression analyses ( Figure 4 ). Log (soluble RAGE) was significantly and positively correlated with log (BNP) (R = 0.48, P < 0.0001, Figure 4a ). Furthermore, log (soluble RAGE) was negatively correlated with EF (R = -0.25, P = 0.003, Figure 4b ).
There were 87 patients with preserved EF (EF > 40%). In patients with preserved EF group, 19 patients had cardiac events. Clinical characteristics of patients with cardiac events and event free patients with preserved EF are shown in Table 3 . Soluble RAGE, BNP and pentosidine were higher in patients with cardiac events than event free patients in preserved EF group.
To determine risk factors for cardiac events, we examined the univariate Cox proportional hazard regression analysis (Table 4) . Serum soluble RAGE, plasma BNP and serum pentosidine were entered as log transformed continuous variables. In the univariate analysis, log (soluble RAGE) was significantly associated with cardiac events (hazard ratio
[HR] 1.64, 95% confidence interval [95% CI] 1.23 -2.19, P = 0.001). Furthermore, age, NYHA functional class, hypertension, creatinine, log (BNP), log (pentosidine) and LVEDV were significantly associated with cardiac events as shown in Table 4 .
Then, those variables with P value of less than 0.05 in the univariate analysis were entered into the multivariate Cox proportional hazard regression analysis. As shown Table 5 , soluble RAGE and pentosidine were independent predictors for cardiac events in patients with heart failure (soluble RAGE: HR 1.90, 95% CI 1.16 -3.09, P = 0.010 and pentosidine: HR 1.59, 95% CI 1.11 -2.29, P = 0.012).
DISCUSSION
In the present study, we showed that serum soluble RAGE level increased with advancing NYHA functional class. Serum soluble RAGE level was also higher in patients with cardiac events than in those without cardiac events. Patients with high soluble RAGE levels had higher cardiac event rates than those with low soluble RAGE levels. The multivariate Cox proportional hazard analysis demonstrated that serum soluble RAGE and pentosidine were independent prognostic factors for heart failure. Since BNP has been widely accepted as a marker of prognosis in patients with heart failure, it is noteworthy that only soluble RAGE and pentosidine, but not BNP, were independent factors to predict prognosis of heart failure in the present study. In the present study, we found that soluble RAGE was increased in patients with cardiac events in heart failure patients with preserved EF (Table 3) . In a previous study, we reported that serum pentosidine levels were increased in patients with cardiac events and preserved EF [9] .
Taken together, these data may suggest that the AGE-RAGE system is at least partially contributed to diastolic heart failure.
Sugiyama et al. reported that plasma pentosidine level was significantly influenced by the quality of glycemic control and renal function [24] . In our present study, patients with renal dysfunction (creatinine > 2 mg/dl) were excluded, and patients with diabetes mellitus were only 24%. Heidland et al. reported that N ε −carboxymethyl lysine (CML) and AGE associated fluorescence (AGE-Fl) were decreased in patients with heart failure, and increased after heart transplantation [25] . In contrast to this report, we previously demonstrated that serum petosidine levels were increased in patients with NYHA class III/IV, and pentosidine was an independent prognostic factor for heart failure [9]. Furthermore, we
showed in the present study that serum soluble RAGE level increased with advancing NYHA functional class and soluble RAGE was a prognostic factor for heart failure. These data may suggest that the AGE-RAGE system is included as one of subcellular mechanisms of heart failure.
To date clinical significance of serum soluble RAGE level is still controversial.
Falcone et al. have reported that low plasma soluble RAGE level is associated with the presence of coronary artery disease in nondiabetic men [14] . However, Nakamura et al.
have reported that serum soluble RAGE levels are significantly higher in type 2 diabetic patients than in non-diabetic subjects and positively associated with the presence of coronary artery disease [15] . It has been reported that RAGE mRNA is up-regulated by the AGEs There are some limitations in the present study. First, it has been reported that some genetic polymorphism exist in the RAGE gene [35] . Jang et al. have investigated the association between the Gly82Ser (G82S) polymorphism in the RAGE gene and circulating levels of soluble RAGE in 1676 nondiabetic and nonobese Korean subjects. In this study, gene distribution was homozygous for the G allele (G/G) were 1180 subjects, heterozygous for the S allele (G/S) were 449 subjects, and homozygous for the S allele (S/S) were 47 subjects. Plasma soluble RAGE levels were significantly higher in subjects with G/G genotype (1038 + 33 pg/ml) than in those with G/S (809 + 19) and the S/S (428 + 43 pg/ml) genotype [36] . Although the distribution of RAGE G82S genotype is still unknown in Japanese population, polymorphism might affect on serum soluble RAGE levels in our study population. Second, the use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers and β-blockers was relatively low in this study. These were data at admission, and there are some reasons for this low rate; (1) many patients were referred to our hospital for admission from general physicians, who were unfamiliar with recent advancement in pharmacotherapy for heart failure including β-blockers, (2) heart failure patients with the first decompensation were included in study population, (3) many of study subjects had preserved left ventricular systolic function (LVEF > 40%) in the present study, and (4) numbers of patients with ischemic heart failure were relatively low (26%) in this study population compared to Western countries. However at discharge, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers and β-blockers 18 were given in 92% and 67% of patients, respectively. Third, in our study population, mean LVEF was high (48±19%). Dilated cardiomyopathy and ischemic heart disease were only 47 patients (29%) and 42 patients (26%), respectively. It is possible that since percentages of dilated cardiomyopathy and ischemic heart disease were low compared to previous studies, the mean LVEF was relatively high in the present study.
Conclusions
Serum soluble RAGE level is related to the severity of heart failure and is an independent predictor for heart failure. Soluble RAGE may be a novel marker for risk stratification of patients with heart failure. Cut-off value of serum soluble RAGE was determined as 1220 pg/ml. 
